In pre-IPO medtech, companies are usually valued at an EV/S multiple of 2–4x, given the high technology intensity, which gives an estimate of around 1.3–2.5 billion rubles. In an especially optimistic scenario, considering its ‘fastest-growing company’ status, the valuation could reach 3 billion rubles...